As well as HR and HER2 status, some studies have indicated that the histological subtype of the breast cancer also plays an important role in predicting the response to adjuvant chemotherapy and/or neoadjuvant chemotherapy (NAC) [16–19]. The gene discussed is ERBB2; the disease is breast cancer.